NOVOMEDLINK™

Access to NovoSeven® RT

Order by Phone

Call 1-877-NOVO-777, Select Option 2
For product orders, operators are available 24 hours a day, 7 days a week. Call 1-877-NOVO-777 and select option 2.

Contact a Distributor

To make stocking NovoSeven® RT easier, the following is a list of vendors who distribute NovoSeven® RT. Simply contact the vendor directly to place your order.

  • ACCREDO HEALTH GROUP, INC.*
    Contact: Rodger Bryant or Rex Sullivan
    201 Great Circle Road
    Nashville, TN 37228
    1-866-721-6118
    hemophiliahealth.com
    HHSCommercialAccounts
    @hemophiliahealth.com

    ASD Healthcare*
    4006 Beltline Road, Suite 200
    Addison, TX 75001
    asdhealthcare.com
    Customer Service:
    1-800-746-6273 (PHON-ASD)

    Cubixx—ASD’s RFID Dispensing Cabinet*
    1-877-428-2499
    1-877-4CUBIXX
    consignment@asdhealthcare.com

    BioCARE/UBS*
    Contact: Sid Lewis
    4405 E Cotton Center Blvd
    Suite 100
    Phoenix, AZ 85040
    1-800-304-3064 (phone)
    1-602-850-6203 (fax)
    biocare-us.org

    Blood Diagnostics Inc.*
    Contact: Jennifer Jacobson
    110 Centrum Drive
    Irmo, SC 29063
    1-800-948-9834
    ivig.com
    jjacobson@ivig.com

    Cardinal Health 108, Inc-SPD*
    Contact: Dominic Crocco
    305 Tech Park Drive, Suite 113
    LaVergne, TN 37086
    1-888-413-4040 or 1-615-287-5341
    cardinal.com
    Dominic.Crocco@Cardinal.Com

  • Caremark*
    Contact: Debby Lynn
    1127 Bryn Mawr Ave
    Redlands, CA 92374-4558
    1-909-799-4187
    caremark.com
    Debby.Lynn@caremark.com

    FFF Enterprises
    Contact: Chris Ground
    Sr. Vice President National Accounts
    41093 Country Center Drive
    Temecula, California 92591
    1-951-296-2500 x1139 (phone)
    fffenterprises.com

    National Hospital Specialties*
    Contact: Elana Ducran
    65 Commerce Way
    Hackensack, NJ 07601
    1-800-344-6087 (phone)
    1-201-488-1174 (fax)
    nhsusa.com
    info@nhsusa.com

    Novis Pharmaceuticals, LLC.*
    Contact: Scott Wise
    5000 SW 75th Ave #121
    Miami, FL 33156
    1-786-437-0700 (phone)
    1-786-437-0686 (fax)
    novispharma.com
    Scott@novispharma.com

    PHS Corporation*
    Contact: Bryan Sanders
    9417 Brodie Lane
    Austin, TX 78748
    1-877-693-4376 (phone)
    1-512-693-4067 (fax)
    phscorporation.com

* Vendor offers consignment programs

Calculate How Much NovoSeven® RT to Order

NovoSeven® RT should be given as early as possible after the start of a bleeding episode.

The recommended initial dose for patients with hemophilia A or B with inhibitors, administered by intravenous bolus injection, is 90 mcg/kg body weight.

The recommended dose range in congenitally FVII-deficient patients is 15-30 mcg/kg body weight.

Recommended dosing for acquired hemophilia is 70-90 mcg/kg every 2-3 hours until hemostasis is achieved.

Following the initial dose of NovoSeven® RT, further injections may be repeated. The duration of treatment and the interval between injections will vary with the severity of the bleed.

Use our online dosing calculator.

New Customer Credit Application

You'll need to print out this form. Fill it out and have it ready when you call Novo Nordisk to order NovoSeven® RT.

Download PDF

You will need Adobe Acrobat Reader to open this file. For a free version, please click here

  1. NovoSeven® RT Coagulation Factor VIIa (Recombinant) Room Temperature Stable Indications and Usage

    NovoSeven® RT is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

    NovoSeven® RT Important Safety Information

    • Most common adverse events: pyrexia, hemorrhage, injection site reaction, arthralgia, headache, hypertension, hypotension, nausea, vomiting, pain, edema, and rash.
    • Patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with activated or nonactivated prothrombin complex concentrates (aPCCs/PCCs) may have a potential risk of developing thrombotic events in association with NovoSeven® treatment.
    • Use with caution in patients with known hypersensitivity to NovoSeven®, its components, or mouse, hamster, or bovine proteins.
    • Serious adverse events that may or may not have been related to the use of NovoSeven® in acquired hemophilia (10 of 139 patients in the compassionate use program, HTRS registry, and the published literature) included thrombotic serious adverse events and death.
    • Serious adverse events that may or may not have been related to the use of NovoSeven® occurred in 14 of 298 patients with hemophilia A or B with inhibitors in the initial clinical program.
    • Development of antibodies against FVII has been reported in FVII-deficient patients after treatment with NovoSeven®. These patients had previously been treated with human plasma and/or plasma-derived FVII.
    • Concomitant use of NovoSeven® RT with other formulations of NovoSeven® is not recommended due to potential dosing errors based on different concentrations.
    • The effect of prolonged post-hemostatic dosing of NovoSeven® RT has not been extensively studied in a clinical setting.

    Please see Prescribing Information.